A groundbreaking new gene therapy could revolutionize heart health treatment by reducing 'bad' cholesterol by up to 60 percent with a single injection. Experts describe the one-off treatment as 'transformative' for patients, offering a powerful new way to prevent future heart attacks and strokes. Published by pharmaceutical company Eli Lilly, the research reveals that this single-infusion drug reduced cholesterol—the fatty plaque that dangerously clogs arteries—by an impressive 60 percent over an 18-month period.
The Struggle with Daily Pills
Currently, over seven million people in the UK rely on daily medications like statins to manage their cholesterol. However, adherence is challenging; studies show that up to half of all patients stop taking their cholesterol medication within the first year, often due to forgetfulness or unpleasant side effects. Compounding the issue, many individuals are unaware they have high cholesterol, which silently builds up due to poor diet, lack of exercise, smoking, and alcohol consumption. It is estimated that six out of ten British adults have dangerously raised cholesterol levels, contributing to 170,000 cardiovascular deaths annually in the UK.
Inside the Breakthrough US Trial
To test the new gene therapy—called VERVE-102—a US-based trial enrolled 35 adults with either a severe inherited form of high cholesterol or a history of early heart attack. The treatment works by disabling a specific gene in the liver that is crucial for producing bad cholesterol. Delivered via a single intravenous transfusion, the therapy reduced LDL ('bad') cholesterol by up to 62 percent at the highest dose tested. Remarkably, when researchers followed up with patients 18 months later, the lower cholesterol levels were fully sustained. These exciting Phase 1 results were published in the New England Journal of Medicine and presented at the European Atherosclerosis Society Congress in Athens.
What the Experts and Patients Say
Professor Riyaz Patel, a consultant cardiologist at Barts Health NHS Trust and professor of cardiology at University College London, shared his excitement: 'It is still early days, but this is an extremely exciting milestone. These findings show the technology works, is safe, and helps lower cholesterol to levels similar to current medicines. The therapy has the potential to provide a 'one and done' approach to a very common condition, which would be transformative in preventing heart attacks and strokes over the long term.' For 41-year-old trial participant Daniel Cullinane, the results are deeply personal. Daniel inherited genetically high cholesterol, discovered only after his father passed away at an early age. Traditional statins were insufficient. 'I was referred to the team at Barts, which led me to being put on the trial,' Daniel shared. 'My cholesterol levels have now dropped, I have lost weight, and I feel a lot healthier.'
Warning on Women's Heart Health
While this medical breakthrough offers immense hope, it arrives alongside a sobering report revealing a major gender gap in healthcare: women are much more likely to face severe delays in diagnosing heart disease and, as a result, are more likely to die from it. An international team led by the European Society of Cardiology is calling for dedicated women's heart centers across Europe to address this dangerous inequality. 'Heart disease kills more women than any other condition—three in ten women globally—yet it remains critically underdiagnosed and undertreated,' warned Dr. Julia Grapsa, lead author of the report. Proving that targeted care can make a difference, a separate study of over 1,300 high-risk women in the US found that a six-month program combining personalized heart health advice with clinical guidelines on blood pressure, diet, and exercise successfully lowered the women's risk of a major life-threatening heart event.
